BIOCARDIO LLC – Trademark Portfolio
Entity Type: 16
BIOCARDIO LLC holds 11 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 10 (Medical Apparatus) — 7 filings in this category. The portfolio also extends into Class 9 (Computers & Electronics) across 4 Nice Classification classes. Currently, 6 trademarks are registered. Notable registered marks include DXMI, ICARDIO, BIOCARDIO, CARDIOVIVO, and CLOUDCARDIO. The owner is based in PASADENA, CA.
789 n. FAIR OAKS AVE
PASADENA, CA 91103
Showing of trademarks Trademarks
Trademark Classifications
BIOCARDIO LLC's trademark portfolio spans 4 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Scientific, nautical, surveying, photographic, cinematographic, optical apparatus and instruments
Medical services; veterinary services; hygienic and beauty care for human beings or animals
Scientific and technological services; industrial analysis and research services
Frequently Asked Questions
How many trademarks does BIOCARDIO LLC have?
BIOCARDIO LLC has 11 U.S. trademarks filed with the USPTO. Of these, 6 registered, 4 abandoned, 1 cancelled.
What trademark classes does BIOCARDIO LLC file in?
BIOCARDIO LLC files trademarks across 4 Nice Classification classes. The most active classes are Class 10 (Medical Apparatus), Class 9 (Computers & Electronics), Class 44 (Medical Services), Class 42 (Computer & Scientific). Class 10 covers surgical, medical, dental and veterinary apparatus and instruments.
What are BIOCARDIO LLC's most well-known trademarks?
BIOCARDIO LLC's registered trademark portfolio includes well-known marks such as DXMI, ICARDIO, BIOCARDIO, CARDIOVIVO, and CLOUDCARDIO. These are among 6 currently registered trademarks in the portfolio.
What is BIOCARDIO LLC's trademark registration success rate?
BIOCARDIO LLC has a 55% trademark registration rate, with 6 out of 11 resolved applications resulting in successful registration. Currently, 0 applications are pending review.